Discovery of novel exceptionally potent and orally active c-MET PROTACs for the treatment of tumors with MET alterations

Various c-mesenchymal-to-epithelial transition (c-MET) inhibitors are effective in the treatment of non-small cell lung cancer; however, the inevitable drug resistance remains a challenge, limiting their clinical efficacy. Therefore, novel strategies targeting c-MET are urgently required. Herein, th...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Pengyun, Jia, Changkai, Fan, Zhiya, Hu, Xiaotong, Zhang, Wenjuan, Liu, Ke, Sun, Shiyang, Guo, Haoxin, Yang, Ning, Zhu, Maoxiang, Zhuang, Xiaomei, Xiao, Junhai, Zheng, Zhibing, Li, Song
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2023
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10326257/
https://www.ncbi.nlm.nih.gov/pubmed/37425039
http://dx.doi.org/10.1016/j.apsb.2023.01.014

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10326257/
https://www.ncbi.nlm.nih.gov/pubmed/37425039
http://dx.doi.org/10.1016/j.apsb.2023.01.014

Ejemplares similares